Inhibiting the interaction of neuropilin-1 (NRP-1) with vascular endothelial growth factor (VEGF) has become an interesting mechanism for potential anticancer therapies. In our previous works, we have obtained several submicromolar inhibitors of this interaction, including branched pentapeptides of general structure Lys(Har)-Xxx-Xxx-Arg. With the intent to improve the proteolytic stability of our inhibitors, we turned our attention to 1,4-disubstituted 1,2,3-triazoles as peptide bond isosteres. In the present contribution, we report the synthesis of 23 novel triazolopeptides along with their inhibitory activity. The compounds were synthesized using typical peptide chemistry methods, but with a conversion of amine into azide completely on so...
AbstractThe development of new antitumor agents is one of the most pressing research areas in medici...
Twenty-six triazole-based derivatives were designed for targeting both PD-L1 (programmed death recep...
International audienceTo find new and better antivascular agents for cancer therapy, a series of com...
<p>Vascular endothelial growth factor (VEGF) and its co-receptor neuropilin-1 (NRP-1) are important ...
Neurotensin (NT) is a regulatory peptide with nanomolar affinity toward NT receptors, which are over...
Peptide-derived protease inhibitors are an important class of compounds with the potential to treat ...
Neuropilin-1 (NRP-1) is a surface receptor found on many types of cancer cells. The overexpression o...
The design, synthesis and biological evaluation of novel triazolyl p38 alpha MAPK inhibitors with im...
We report the molecular design and synthesis of EG00229, <b>2</b>, the first small molecule ligand f...
We report the molecular design and synthesis of EG00229,2, the first small molecule ligand for the V...
Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) is essential for physiological fu...
In our drug discovery program, a series of 2-thioxo-pyrazolo[1,5-a][1,3,5] triazin-4-ones were desig...
The epidermal growth factor receptor (EGFR) is overexpressed in multiple carcinomas and is the focus...
HPLW is a Vascular Endothelial Growth Factor (VEGF)-mimicking beta-hairpin peptide endowed of proang...
The epidermal growth factor receptor (EGFR) is overexpressed in multiple carcinomas and is the focus...
AbstractThe development of new antitumor agents is one of the most pressing research areas in medici...
Twenty-six triazole-based derivatives were designed for targeting both PD-L1 (programmed death recep...
International audienceTo find new and better antivascular agents for cancer therapy, a series of com...
<p>Vascular endothelial growth factor (VEGF) and its co-receptor neuropilin-1 (NRP-1) are important ...
Neurotensin (NT) is a regulatory peptide with nanomolar affinity toward NT receptors, which are over...
Peptide-derived protease inhibitors are an important class of compounds with the potential to treat ...
Neuropilin-1 (NRP-1) is a surface receptor found on many types of cancer cells. The overexpression o...
The design, synthesis and biological evaluation of novel triazolyl p38 alpha MAPK inhibitors with im...
We report the molecular design and synthesis of EG00229, <b>2</b>, the first small molecule ligand f...
We report the molecular design and synthesis of EG00229,2, the first small molecule ligand for the V...
Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) is essential for physiological fu...
In our drug discovery program, a series of 2-thioxo-pyrazolo[1,5-a][1,3,5] triazin-4-ones were desig...
The epidermal growth factor receptor (EGFR) is overexpressed in multiple carcinomas and is the focus...
HPLW is a Vascular Endothelial Growth Factor (VEGF)-mimicking beta-hairpin peptide endowed of proang...
The epidermal growth factor receptor (EGFR) is overexpressed in multiple carcinomas and is the focus...
AbstractThe development of new antitumor agents is one of the most pressing research areas in medici...
Twenty-six triazole-based derivatives were designed for targeting both PD-L1 (programmed death recep...
International audienceTo find new and better antivascular agents for cancer therapy, a series of com...